Search Results

27 results

  1. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 62

    Nasal mucociliary clearance is a physiologically-relevant biomarker of tobacco effect/potential harm

    MAKENA P.; BAXTER S.; JONES B.A.; EVANS E.H.; CHEN P.; KREBS H.; GILL R.K.; PRASAD G.L.
    RAI Services Company, Winston-Salem, NC, U.S.A.
    Chronic cigarette smoking increases the risk of several diseases including chronic obstructive pulmonary disease (COPD). The pathophysiology of COPD can be attributed to multiple components: mucociliary dysfunction, airway inflammation and structural ...
  2. TSRC, Tob. Sci. Res. Conf., 2018, 72, abstr. 074

    Urinary leukotriene E4 and 2,3-dinor thromboxane B2 are potential biomarkers of effect for tobacco product evaluations

    MAKENA P.; LIU Gang; NOURI N.; CHEN P.; PRASAD G.L.
    RAI Services Company, Winston-Salem, NC, USA
    Adverse health outcomes from cigarette smoking generally take several decades to develop. Physiologically-relevant biomarkers of effect (BioEff), such as FEV1, typically require sustained smoking abstinence over several months to detect a significant ...
  3. TSRC, Tob. Sci. Res. Conf., 2015, 69, abstr. 53

    Influence of cigarette filter ventilation on smokers’ mouth level exposure to tar and nicotine: a retrospective meta-analysis of 11 studies in 9 countries

    FEARON I.M.(1); BOWMAN S.A.(2); CARAWAY J.W.(2); CHEN P.(2); NELSON P.R.(2); ASHLEY M.(1); SHEPPERD C.J.(1); ERRINGTON G.(1)
    (1) British American Tobacco (Investments) Limited, Southampton, UK; (2) R.J. Reynolds Tobacco Company, Winston-Salem, NC USA
    Cigarette filter ventilation allows air to be drawn into the mainstream smoke which, when the ventilation is unblocked, dilutes the smoke. When cigarettes are machine-smoked using the Health Canada Intense method, ventilation holes are blocked and this ...
  4. CORESTA Congress, Quebec, 2014, Smoke Science/Product Technology Groups, ST 81

    Clinical trial to compare smoking cessation rates with Camel SNUS and a nicotine lozenge – Part 1: Study Design

    NELSON P.R.; CHEN P.
    R.J. Reynolds Tobacco Company, Winston-Salem, NC, U.S.A.
    R.J. Reynolds conducted a multicenter clinical trial to compare smoking cessation rates when healthy smokers with the intent to quit were switched to Camel SNUS or a nicotine lozenge. The primary objectives of the study examined whether SNUS was superior ...
  5. CORESTA Congress, Quebec, 2014, Smoke Science/Product Technology Groups, ST 82

    Clinical trial to compare smoking cessation rates with Camel SNUS and a nicotine lozenge – Part 2: Results

    NELSON P.R.; CHEN P.
    R.J. Reynolds Tobacco Company, Winston-Salem, NC, U.S.A.
    R.J. Reynolds conducted a multicenter clinical trial to compare smoking cessation rates with Camel SNUS, with and without smokeless tobacco health-related background information, and a nicotine lozenge. Cessation was evaluated using Fisher’s exact test ...
  6. TSRC, Tob. Sci. Res. Conf., 2014, 68, abstr. 07

    Retrospective analysis of data from cigarette smoke mouth level exposure (MLE) studies

    BOWMAN S.A.; CARAWAU J.; CHEN P.; NELSON P.R.
    R.J. Reynolds Tobacco Company, Winston-Salem, North Carolina, USA
    Over the past eight years, R.J. Reynolds Tobacco Company conducted a series of cigarette smoke mouth-level exposure (MLE) studies. In those studies, used cigarette filters were analyzed to determine per cigarette and daily MLE to “tar” and nicotine. In ...
  7. TSRC, Tob. Sci. Res. Conf., 2014, 68, abstr. 33

    Assessment of exposure biomarkers in U.S. consumers of snus, moist snuff, cigarettes, and dual use

    CARAWAY J.W.; JONES B.A.; CHEN P.; BORGERDING M.F.
    R.J. Reynolds Tobacco Company, Winston-Salem, North Carolina, USA
    Biomarkers of exposure (BoE) to constituents in tobacco products and tobacco smoke were assessed in adult, U.S. tobacco consumers who participated in a multi-center, cross-sectional study. A total of 320 subjects (267 males/53 females) were enrolled in ...